CD8+ T-cell-mediated Interface Dermatitis after CCR4+ T-cell Depletion by Mogamulizumab Treatment of Adult T-cell Leukaemia/lymphoma

Acta Derm Venereol. 2017 Mar 10;97(3):377-378. doi: 10.2340/00015555-2555.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antineoplastic Agents / adverse effects*
  • Biomarkers, Tumor / analysis*
  • Biopsy
  • CD8-Positive T-Lymphocytes / drug effects*
  • CD8-Positive T-Lymphocytes / immunology
  • Diagnosis, Differential
  • Drug Eruptions / diagnosis
  • Drug Eruptions / drug therapy
  • Drug Eruptions / etiology*
  • Drug Eruptions / immunology
  • Glucocorticoids / therapeutic use
  • Humans
  • Leukemia-Lymphoma, Adult T-Cell / drug therapy*
  • Leukemia-Lymphoma, Adult T-Cell / immunology
  • Leukemia-Lymphoma, Adult T-Cell / pathology
  • Male
  • Predictive Value of Tests
  • Prednisolone / therapeutic use
  • Receptors, CCR4 / analysis*
  • T-Lymphocytes, Regulatory / drug effects*
  • T-Lymphocytes, Regulatory / immunology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • CCR4 protein, human
  • Glucocorticoids
  • Receptors, CCR4
  • Prednisolone
  • mogamulizumab